Ozempic Side Effects: Risks & What to Know
- Semaglutide, found in drugs like Ozempic and Wegovy, has become widely known for common side effects such as diarrhea and facial changes.
- Dr.Daniel Drucker, an endocrinologist at the Lunenfeld-Tanenbaum Research Institute in Toronto, notes that gallbladder issues are a real concern.The gallbladder stores bile, which aids in fat digestion.
- While elevated amylase and lipase levels,along with abdominal pain,can suggest pancreatitis,Drucker says imaging scans rarely show pancreatic abnormalities when GLP-1 drugs are the apparent cause.
Navigate the complexities of Ozempic and Wegovy side effects with clarity. This article from News Directory 3 cuts through the noise, detailing the truths and dispelling myths surrounding these popular GLP-1 drugs. Understand the risks: gallbladder issues, kidney problems, and allergic reactions are real possibilities. Seperate fact from fiction regarding pancreatitis and thyroid cancer, diving into expert opinions and the latest research. We break down the FDA warnings and what thay mean for you, exploring the nuances of semaglutide and tirzepatide. Gain crucial insights into potential adverse events and learn how to make informed decisions about your health. discover what’s next …
Ozempic, Wegovy: Sorting Fact From Fiction on Side Effects
Updated June 15, 2025
Semaglutide, found in drugs like Ozempic and Wegovy, has become widely known for common side effects such as diarrhea and facial changes. Though, the U.S. Food and drug Administration (FDA) labels highlight rarer but more serious potential adverse events,including gallbladder disease,kidney issues,allergic reactions,pancreatitis,and thyroid cancer. While these complications are considered uncommon,it’s crucial to understand their warning signs and prevalence.
Dr.Daniel Drucker, an endocrinologist at the Lunenfeld-Tanenbaum Research Institute in Toronto, notes that gallbladder issues are a real concern.The gallbladder stores bile, which aids in fat digestion. GLP-1 drugs have been linked to cholelithiasis (gallstone formation) and cholecystitis (gallbladder inflammation). Gallstones can block bile release, leading to inflammation and symptoms like sharp abdominal pain, jaundice, and gastrointestinal distress, especially after fatty meals. Imaging tests can confirm gallstones.
While elevated amylase and lipase levels,along with abdominal pain,can suggest pancreatitis,Drucker says imaging scans rarely show pancreatic abnormalities when GLP-1 drugs are the apparent cause. Extensive data now indicates that GLP-1 drugs like Ozempic likely do not cause pancreatic disorders.
Regarding thyroid cancer, the FDA includes a black box warning on Ozempic, Wegovy, mounjaro, and Zepbound labels due to thyroid C-cell tumors in rodents. However, experts believe this risk is minimal in humans. Dr. Elizabeth Pearce, an endocrinologist at Boston Medical Center, states that human studies have not shown the same effects as in rodents. A Scandinavian study found a lower incidence of thyroid cancer in GLP-1 users compared to a control group. European regulators also found no link between GLP-1 drugs and thyroid cancer in 2023.
Tirzepatide (Mounjaro, Zepbound), a newer dual agonist that mimics GLP-1 and GIP hormones, carries similar warnings. While it causes more weight loss than semaglutide, it may not increase the risk of severe side effects. Drucker suggests that GIP might mitigate some adverse events induced by GLP-1.
The new generation of GLP-1 drugs carries warnings,but experts agree that some side effects,like pancreatitis and thyroid cancer,are unlikely to be caused by these drugs. However, gallbladder disease, kidney injury, and allergic reactions remain real possibilities.
what’s next
Ongoing research continues to monitor the long-term effects of GLP-1 drugs and tirzepatide, providing more data on their safety profiles and potential risks. Patients should discuss any concerns with their healthcare providers and stay informed about the latest findings.